Hope Rugo

MD

Breast oncologist

About me

Dr. Hope Rugo is a hematologist-oncologist who specializes in breast cancer treatment. She joined the UCSF Carol Franc Buck Breast Care Center after a decade at UCSF Medical Center, where she worked in bone marrow transplantation for a variety of diseases, including breast cancer.

Rugo is co-director of UCSF's breast cancer clinical trials program. She is the principal investigator for several clinical trials of potential new therapies. She is also an investigator with the Bay Area's SPORE (Specialized Programs of Research Excellence) on breast cancer. The National Cancer Institute established SPORE to foster collaborative, interdisciplinary cancer research.

  • Education

    University of Pennsylvania School of Medicine, 1984

  • Residencies

    UCSF Medical Center, Internal Medicine, 1987

  • Fellowships

    UCSF Medical Center, Hematology, 1990

    UCSF Medical Center, Oncology, 1995

  • Board Certifications

    Internal Medicine, American Board of Internal Medicine

    Medical Oncology, American Board of Internal Medicine

  • Academic Title

    Professor

  • Languages

    French

    Spanish

Conditions I specialize in

Carol Franc Buck Breast Care Center

Bakar Precision Cancer Medicine Building

1825 Fourth St., Third Floor
San Francisco, CA 94158

(415) 353-7070
M-F, 8 a.m. - 5 p.m.

My reviews

4.7

Overall Experience
250 Reviews
I feel very lucky Dr. Rugo is my Oncologist. She is wise and compassionate I have total confidence in her.
Explained things in a way that was easy to understand
250 Reviews
Did the doctor pay attention to your concerns
249 Reviews
Gave easy to understand instructions about taking care of health problems or concerns
239 Reviews
Knew the important information about your medical history
246 Reviews
The provider showed respect for what you had to say
248 Reviews
The provider spent enough time with me
249 Reviews
Read all reviews About our process

Selected research

Decorative Caduceus

Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo...

The outcome measure of the study is IDFS, defined by the STEEP system as the first occurrence of the time from the date of randomization to the date of first invasive disease recurrence (local, regional or distant), the date of se...

Recruiting

Decorative Caduceus

The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanc...

Progression Free Survival is defined from the time from randomization to the first occurrence of disease progression as determined by the investigator using RECIST 1.1 or death from any cause, whichever occurs first.

Recruiting

Decorative Caduceus

A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Pos...

PFS defined as the time from the date of randomization to the first evidence of disease progression as defined by response evaluation criteria in solid tumors (RECIST) v1.1 or death from any cause. Progressive Disease (PD) was at ...

Recruiting

Decorative Caduceus

A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positiv...

Recruiting

Decorative Caduceus

Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer

Assessment of DLT and determination of MTD

Recruiting

Decorative Caduceus

A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Pal...

Recruiting

Decorative Caduceus

Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Pr...

Assess the percentage of patients without disease progression based on local investigator assessment per RECIST in cohort A, cohort B and cohort C. Each cohort will be assessed when last patient in each cohort has reached 6 months...

Recruiting

Decorative Caduceus

A Safety Study of SGN-LIV1A in Breast Cancer Patients

Recruiting

Decorative Caduceus

Pembrolizumab With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Che...

Disease control will also be based on PD-L1 expression via immunohistochemistry

Recruiting

Decorative Caduceus

Avelumab With Binimetinib, Utomilumab, or Anti-OX40 Antibody PF-04518600 in Treating Triple Neg...

Will be defined as the percentage of patients achieving complete response or partial response by RECIST version 1.1 and will be reported for each arm along with 95% two-sided confidence intervals.

Recruiting

Contact me

Providers on my team

Share